Immuron Granted US Patent for NASH Treatment Melbourne, Australia

Granted US Patent for NASH Treatment

Australia, November 14, 2017: Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company

focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today pleased

to announced that a Notice of Allowance has been received from the United States Patent and Trademarks Office (USPTO) for Immuron's

new patent application (U.S Application No. 13/817,414), entitled "Anti-LPS Enriched Immunoglobulin for Use in treatment

and/or Prophylaxis of a Pathological Disorder."

patent comprises of a total of ten allowed claims, and is principally directed to a method of treating non-alcoholic steatohepatitis

(NASH) with a colostrum-based composition, as developed by Immuron. The market for NASH treatment has come under increased focus,

as companies including Bristol-Myers Squibb and Pfizer have referenced efforts to bolster their product development in the sector.

According to Reuters, the NASH market is "forecast to be $20 billion to $35 billion as populations with fatty diets increasingly

fall victim to a condition with no approved treatments," further illustrating why the pharmaceutical industry refers

to the race to commercialize technology in this sector as "The Dash to NASH."

new patent is a key milestone for Immuron as it further establishes the intellectual property position of our NASH program in

the United States and complements the patents already granted in Australia," said Jerry Kanellos, Interim CEO of Immuron

Ltd. "We believe this success paves the way for patent grants in other key jurisdictions, strengthening Immuron's

presence in the global NASH treatment market."

Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment

of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic

cycle. The Company currently markets and sells Travelan for the prevention of travellers' diarrhea whilst its lead

product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company's other

preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet

need in the market. For more information visit: http://www.immuron.com

IMM-124E study is a Phase 2 proof of concept multinational, randomized, double-blind study comparing 2 doses IMM-124E to placebo

for the treatment of NASH in adults with any stage biopsy-proven NASH. The trial enrolled 133 patients and is still on going.

The primary endpoint is the improvement of liver steatosis as assessed by MRI comparing the mean values), as measured at the 24

weeks' time point. The key secondary endpoints are: change in ALT as well as other liver enzymes and metabolic markers.

enrolled adults with all-stage biopsy proven NASH up to 12 months of randomization.

is an oral, three-times-daily, non-absorbable compound containing poly-clonal anti-LPS immunoglobulins proposed to interact with

the gut LPS and immune system to achieve an immunomodulatory effect reducing LPS-related inflammation and inducing tolerance.

Because of this unique mechanism of action, targeting multiple pathways, IMM-124E has the potential to play a differentiated role

in the management of NASH and may form the cornerstone of NASH combination treatment strategies, both as a single agent and in

combination with other agents.

addition to the adult NASH study, IMM-124E is also being evaluated in the pediatric population in a Phase 2 proof-of-concept study

of IMM-124E in children with Pediatric NAFLD.

Non-Alcoholic Steatohepatitis (NASH)

is a severe type of non-alcoholic fatty liver disease (NAFLD), which is characterized by the accumulation of fat in the liver

with no other apparent causes. NASH occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage.

The inflammation can lead to fibrosis (scarring) of the liver and eventually progress to cirrhosis, portal hypertension, liver

cancer, and eventual liver failure.

is an emerging health crisis impacting 3% to 5% of the U.S. population and 2% to 4% globally, and is the fastest growing cause

of liver cancer and liver transplant in the U.S. The increasing prevalence of NASH is attributed to the growing obesity epidemic

and the disease is often diagnosed in patients who have diabetes, high cholesterol or high triglycerides. There is currently no

approved treatment for NASH.

press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of

1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,

any statements relating to our growth strategy and product development programs and any other statements that are not historical

facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties

that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual

results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,

perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and

development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical

and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the

early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual

property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking

to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations

or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.